Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood tests and clinical data.
Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood tests and clinical data.
Designed by doctors. Powered by AI.
Owned by you.